Not Signed In -
Warts, Genital |
Anal Warts |
Clinical Trial: Broad Spectrum HPV Vaccine Dose Ranging Study
This study is not yet open for patient recruitment.
Verified by Merck December 2005
|
Purpose
This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23 years of age at enrollment.
| Condition | Intervention | Phase |
|---|---|---|
| HPV; Cervical Cancer and Premalignancy; Anogenital Warts | Vaccine: V502 | Phase II |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Bio-equivalence Study
Further study details as provided by Merck:
Study start: December 2005
Eligibility
Ages Eligible for Study: 16 Years - 23 Years, Genders Eligible for Study: Female
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Lifetime history of 0-4 sexual partners
Exclusion Criteria:
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00260039
Toll Free Number 1-888-577-8839
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_086
Last Updated: December 5, 2005
Record first received: November 28, 2005
ClinicalTrials.gov Identifier: NCT00260039
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10
Last Updated: December 5, 2005
Record first received: November 28, 2005
ClinicalTrials.gov Identifier: NCT00260039
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10
email this page
print this page
bookmark this page
feedback on this page
